Free Trial

Q3 Earnings Forecast for Danaher Issued By Leerink Partnrs

Danaher logo with Medical background

Danaher Corporation (NYSE:DHR - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for shares of Danaher in a research note issued to investors on Tuesday, July 22nd. Leerink Partnrs analyst P. Souda now forecasts that the conglomerate will post earnings per share of $1.71 for the quarter, down from their previous forecast of $1.75. The consensus estimate for Danaher's current full-year earnings is $7.63 per share. Leerink Partnrs also issued estimates for Danaher's Q4 2025 earnings at $2.37 EPS, FY2025 earnings at $7.76 EPS, Q1 2026 earnings at $2.15 EPS, Q2 2026 earnings at $2.01 EPS, Q3 2026 earnings at $1.84 EPS, Q4 2026 earnings at $2.56 EPS and FY2026 earnings at $8.56 EPS.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the company earned $1.72 EPS. Danaher's revenue was up 3.4% on a year-over-year basis.

DHR has been the subject of a number of other reports. Robert W. Baird raised their target price on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. TD Cowen raised their target price on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, HSBC dropped their target price on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

View Our Latest Report on Danaher

Danaher Price Performance

Shares of NYSE:DHR traded up $2.79 during midday trading on Thursday, reaching $205.60. The company's stock had a trading volume of 5,355,676 shares, compared to its average volume of 3,965,185. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a market capitalization of $147.22 billion, a P/E ratio of 43.74, a P/E/G ratio of 2.86 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.05. The business's fifty day simple moving average is $196.38 and its 200-day simple moving average is $203.68.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. GHP Investment Advisors Inc. grew its stake in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the period. Heck Capital Advisors LLC acquired a new position in shares of Danaher during the fourth quarter worth about $27,000. Sierra Ocean LLC boosted its position in shares of Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after buying an additional 76 shares during the period. Red Tortoise LLC boosted its position in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock worth $30,000 after buying an additional 98 shares during the period. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Danaher during the first quarter worth about $31,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 25th. Investors of record on Friday, June 27th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. Danaher's dividend payout ratio is presently 27.23%.

About Danaher

(Get Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Recommended Stories

Earnings History and Estimates for Danaher (NYSE:DHR)

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines